We went with the non-ambulant population because the research from Pinto Mariz showed that CD49D was substantially higher in older, non-ambulant boys, and ATL1102 targets CD49D. Also, as a small, scrappy biotech with limited resources, it is important to go after unmet needs with limited competition. And, at least when ANP starting embarking down the DMD path in 2017, there was substantially less competition in the non-ambulant space compared to the ambulant space.
We went with the non-ambulant population because the research...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.4¢ |
Change
-0.001(1.18%) |
Mkt cap ! $75.73M | |||
| Open | High | Low | Value | Volume |
| 8.9¢ | 8.9¢ | 8.2¢ | $63.67K | 761.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 43210 | 8.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.7¢ | 200 | 1 |
View Market Depth
| Last trade - 15.59pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
8.4¢ |
Change
-0.001 ( 3.45 %) |
||||
| Open | High | Low | Volume | ||
| 8.9¢ | 8.9¢ | 8.2¢ | 115933 | ||
| Last updated 14.43pm 07/06/2024 ? | |||||
| PER (ASX) Chart |